Staphylococcus aureus (MRSA). In vitro studies demonstrated bacterial re-growth and development of rifampin resistance after 24 h with rifampin alone, which was prevented under hyperthermic conditions. For the in vivo studies, rifampin was administered intraperitoneally every 12 h for 7 days to rabbits with MRSAcontaining cages implanted into their flanks.
Introduction
Implanted devices are increasingly used in modern medicine to improve function (e.g. internal fixation, neurosurgical shunts, prosthetic heart valves), to alleviate pain (e.g. prosthetic joints), or for aesthetic reasons (e.g. breast implants). 1 Despite the use of perioperative antimicrobial prophylaxis, infection of the implant can occur, since less than 100 colony forming units (cfu) of micro-organisms can cause an infection when a foreign body is present. 2 If infection occurs, it causes high morbidity and substantial cost, especially in orthopaedic surgery. 3 Until recently, standard treatment approaches to these infections in orthopaedic surgery included removal or replacement of all foreign-body material. 4 Since this surgical concept is invasive, may cause considerable tissue damage and requires prolonged hospital stay, its use has been challenged. 5 -7 G-Y Zou, H Shen, Y Jiang et al.
Rifampin and focal hyperthermia for foreign-body infections
Staphylococcus aureus is the most common pathogen causing implant-associated infections. 8, 9 Successful chemotherapeutic treatment of device-associated infection requires an antimicrobial agent that acts against surface-adhering micro-organisms in the stationary growth phase. Rifampin is bactericidal against stationary growth-phase staphylococci, as demonstrated in vitro, in experimental animal models and in clinical studies. 10, 11 When used as a single agent, however, rapid emergence of rifampin resistance occurs. 12, 13 Thus, antimicrobial combinations were investigated to determine if they could prevent the development of rifampin resistance during treatment. 12, 14, 15 Rifampin in combination with other antimicrobial agents has been successfully used for the treatment of orthopaedic implant-related infections. 16 -18 The increasing prevalence of drug-resistant staphylococci has, however, driven the search for alternative drugs for combination treatment with rifampin. 19, 20 Due to their resistance to a range of antimicrobials, methicillin-resistant staphylococci present an increasing challenge. 21, 22 An alternative therapy that overcomes these shortcomings is, therefore, of interest.
Focal hyperthermia in combination with chemotherapy has been widely used for the treatment of liver and colorectal tumours. 23 The most important mechanisms for an interactive effect are an increased intracellular drug uptake, enhanced DNA damage and higher drug concentrations, resulting from an increase in blood flow. 24 Hyperthermia is part of a host's response to infection and it has been demonstrated to be associated with improved outcomes, 25 -28 due, at least in part, to an apparent restriction of bacterial growth. Experimental studies with Streptococcus pneumoniae meningitis demonstrated reduced in vivo bacterial growth rates in rabbits with elevated body temperatures. 29, 30 The animal model of foreign-body infection has been widely used and has provided relevant data about the efficacy of several antibiotics, alone and in combination, which may be applied to the treatment of human prosthetic infections. 31 -34 This model includes (i) bacterial populations attached to coverslips forming a surface-adherent biofilm, and (ii) other bacterial populations that directly detach from the biofilm and grow in the tissue cage fluid (TCF). Both populations are highly resistant to antibiotics, 35 and the activity of antibiotics diminishes in parallel in both bacterial populations. This foreign-body infection model was used in the present study to investigate the effect of focal hyperthermia on the efficacy of rifampin against one reference methicillin-resistant Staphylococcus aureus (MRSA) strain.
Materials and methods

STUDY MICRO-ORGANISM
The MRSA strain ATCC 29213 was used in this study. It was stored at -70°C using a cryovial bead preservation system (Microbank; Pro-Lab Diagnostics, Richmond Hill, Ontario, Canada). One cryoculture bead was incubated in 1 ml of brain heart infusion broth for 7 h at 37°C without shaking. Cultures were then diluted 1:100 in 5 ml of brain heart infusion broth and incubated overnight at 37°C without shaking. Subsequently, bacteria were centrifuged at 4000 g for 10 min, and the pellet was washed twice and resuspended in pyrogen-free 0.9% NaCl before use.
ANTIMICROBIAL AGENT
For in vitro studies, purified rifampin powder was resuspended according to the manufacturer's laboratory recommendations.
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For in vivo experiments, the commercial rifampin product was used, diluted to achieve a final volume that could be administered to animals. The rifampin was supplied by Aventis Pharma Ltd (West Malling, UK).
IN VITRO ANTIMICROBIAL SUSCEPTIBILITY
In vitro susceptibility of MRSA to rifampin was determined in triplicate using a standard inoculum of 1 -5 × 10 5 cfu/ml, adjusted from overnight cultures. The minimum inhibitory concentration (MIC) was determined in Mueller-Hinton broth (MHB) by the macrodilution method. 10 In brief, 10 two-fold serial dilutions of the test drug were prepared in 2 ml MHB in sterile borosilicate glass tubes. A 2-ml aliquot of the antimicrobial dilutions were inoculated below the meniscus and incubated for 18 h at 37°C without shaking. The MIC was the lowest drug concentration that inhibited visible bacterial growth. Tubes without visible growth were then vigorously vortexed, incubated for 4 h at 37°C without shaking and assessed for viable bacteria by plating on agar. The lowest antimicrobial concentration that killed > 99.9% of the initial bacterial count (i.e. ≥ 3 log 10 cfu/ml) was defined as the minimum bactericidal concentration during logarithmic growth (MBC log ), as described in the Manual of Clinical Microbiology. 36 Killing of bacteria during stationary growth phase (MBC stat ) was assayed in nutrient-restricted medium (0.01 M phosphate-buffered saline [PBS], pH 7.4), as previously described. 15 In this medium, bacterial counts remained within ±15% of the initial inoculum in the antimicrobial-free culture for > 36 h.
IN VITRO TIME-KILL CURVES
Time-kill curves to test bactericidal activities were determined for bacteria in the exponential-and stationary-phases of growth. In vitro studies in the log-phase were carried out following standard recommendations; the antibiotic concentrations tested were multiples of the MIC (0.5 -12 × MIC). The methodology used in the stationary-phase studies was previously shown to be a reliable method to predict in vivo antimicrobial activity in foreign-body infections. 13 Bacteria in the stationary phase were used in the present study, obtained as described by Widmer et al. 14 and resuspended in a nutrient-restricted medium. The prefixed concentrations of antibiotic tested in the in vitro studies, 8 and 4 µg/ml of rifampin, were equivalent to peak and trough levels in TCF, respectively. To investigate possible synergy between the rifampin and hyperthermic combinations, subinhibitory concentrations of rifampin (0.5 × MIC) were also tested. For both experiments (log and stationary phases), bactericidal activity was defined as a ≥ 3 log 10 decrease in the initial inoculum in cfu/ml at 24 h. The results of the rifampinhyperthermic combination treatment were compared with the most active concentration of rifampin alone; synergy, indifference and antagonism were then defined as a ≥ 2 log increase in killing, < 1 log change (increase or decrease) in killing and ≥ 2 log decrease in killing, respectively. To avoid carry-over antimicrobial agent interference, the sample was placed on the plate in a single streak down the centre and allowed to absorb into the agar until the plate surface appeared dry. The inoculum was then spread over the plate.
IN VITRO ANTIMICROBIAL RESISTANCE STUDIES
An assay to evaluate the rate of in vitro emergence of rifampin resistance was G-Y Zou, H Shen, Y Jiang et al.
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developed. The ratio of resistant versus total colony counts was assessed after a 24-h incubation of the MRSA strain in 10 ml MHB containing rifampin alone at 1 × MIC, or rifampin 1 × MIC in combination with hyperthermia at 39°C, 41°C or 43°C. The 24-h bacterial cultures were serially diluted 10-fold and 50-µl aliquots were plated on Mueller-Hinton agar (MHA) containing either rifampin (1 µg/ml) or no antibiotic (saline control), and colonies were counted after 48 h of incubation at 37°C. The results were expressed as the ratio between the rifampin-resistant and the total log 10 cfu/ml. Experiments were performed in triplicate.
ANIMAL MODEL
The study was previously approved by the Ethical Committee for Animal Experiments at Shanghai Jiaotong University. For the surgical procedure, rabbits were anaesthetized with an intramuscular injection of ketamine (20 mg/kg body weight) and xylazine (4 mg/kg). To obtain samples during the experiment, the rabbits were anaesthetized with isofluorane. Sacrifice of the rabbits was by cardiac puncture with thiopental. The rabbit model was as previously described by Lucet et al., 31 with some modifications. In brief, two multiperforated polytetrafluoroethylene (Teflon) tissue cages (with internal and external diameters of 10 and 12 mm, respectively, and a length of 15 mm) containing two polymethylmethacrylate coverslips (7 × 7 × 1 mm), perforated with 120 regularly spaced holes of 1-mm diameter, were subcutaneously implanted in the flanks of male New Zealand rabbits (weight 640 -800 g) under aseptic conditions.
A positive temperature coefficient (PTC) device coated with aluminium oxide was embedded in the cage; this device can reach the required temperature within 1 min and maintain it after charging with 9 V of direct current, then return the temperature to about 37°C within 2 min after discharging. During the focal hyperthermia treatment, the PTC devices were charged for 20 min a day to raise the cage temperature to the required temperature. At 1 week after surgery, after complete healing of the wounds, TCFs were percutaneously obtained and checked for sterility. When bacterial contamination was excluded, cages were infected by percutaneous inoculation of 200 µl of overnight culture containing 2 × 10 6 cfu S. aureus for treatment evaluation. Established infection was confirmed 24 h later by culture of aspirated TCF.
PHARMACOKINETIC STUDIES
To relate the pharmacokinetics of rifampin to its efficacy, concentrations of rifampin in TCF were determined by a bioassay using Micrococcus luteus as previously described. 37 The bioassay detection limit for rifampin was 1.25 µg/ml. Aliquots of 150-µl of TCF were aspirated from non-infected animals at 1, 2, 4, 6, 8, 10, 12 and 24 h following intraperitoneal administration of a single dose of rifampin at 12.5 mg/kg at 39°C, 41°C or 43°C. Each temperature was tested in three rabbits using two cages per rabbit, giving a total of 18 cages. The collected TCF was centrifuged (2100 g for 7 min) and the supernatant stored at -20°C until further analysis. The concentration-time data were analysed individually for each rabbit using the WinNonlin software package (Pharsight Corp., Mountain View, CA, USA). Mean ± SD values of the peak concentration (C max ), time to reach the peak concentration (t max ), trough concentration at 12 h after dosing (C min ), half-life (t ½ ), and the area under the concentration-time curve during 24 h (AUC 0 -24 ) were calculated. The bioassay detection limit corresponded to the rifampin MIC of the indicator organism (i.e. 1.25 µg/ml).
ANTIMICROBIAL TREATMENT
Antimicrobial treatment was initiated 24 h after infection (day 1). At least three rabbits were randomized into each of the following treatment groups: control (saline), rifampin 12.5 mg/kg alone, and rifampin 12.5 mg/kg combined with hyperthermia at 39°C, 41°C or 43°C. All antibiotic doses were administered intraperitoneally every 12 h.
ANTIMICROBIAL EFFICACY AGAINST PLANKTONIC BACTERIA
Planktonic bacteria were enumerated in aspirated TCF before initiation of antimicrobial treatment (day 1), on the sixth day of treatment, immediately before the last antimicrobial dose (day 7) and 3 days after the end of treatment (day 10). Bacterial counts were expressed as the median and interquartile range of log 10 cfu/ml. The quantification limit of planktonic bacteria was set at 2000 cfu/ml (> 10 cfu in 50 µl from dilutions > 100-fold). Thus, negative TCF cultures were assigned a value of 3 log 10 cfu/ml for calculating the log 10 cfu/ml reduction and for statistical analysis. Treatment efficacy against planktonic bacteria was expressed as (i) the difference in bacterial counts in the TCF (∆ log 10 cfu/ml = log 10 cfu/ml at days 7 or 10 -log 10 cfu/ml at day 1), and (ii) the rate of culture-negative TCF samples (the number of TCF samples without detectable growth of MRSA/the total number of cages in the treatment group).
ANTIMICROBIAL EFFICACY AGAINST ADHERENT BACTERIA
To determine the antimicrobial efficacy against adherent bacteria, rabbits were sacrificed on day 10. Cages were removed under aseptic conditions and placed in 5 ml trypticase soy broth (TSB), vortexed for 30 s and incubated at 37°C. After 48 h, 100-µl aliquots of cage cultures were plated on Columbia sheep blood agar plates (Becton, Dickinson & Co., Franklin Lakes, NJ, USA) and assessed for bacterial growth. Cultures displaying growth were tested with the S. aureus latex test (Staphytect Plus; Oxoid, Basel, Switzerland). Negative probes in this test were considered contaminated and were not used for the evaluation of treatment efficacy. Treatment efficacy against adherent bacteria was expressed as cure rate (the number of cage cultures without growth of MRSA/the total number of cages in the treatment group).
IN VIVO ANTIMICROBIAL RESISTANCE STUDIES
Positive cultures from TSB containing explanted cages (i.e. treatment failures) were screened for in vivo development of rifampin resistance. For this purpose, multiple colonies of each morphologically distinct colony type were collected from an agar subculture, suspended in saline to a standardized inoculum corresponding to a turbidity of McFarland 0.5 and plated on MHA containing 1 µg/ml rifampin. Plates were incubated at 37°C and screened for growth after 48 h.
STATISTICAL ANALYSIS
Comparisons were performed using the Mann-Whitney U-test for continuous variables and using two-sided χ 2 or Fisher's exact tests for categorical variables, as appropriate. For all tests, differences were considered statistically significant when Pvalues were < 0.05. Table 1 shows the in vitro susceptibility of MRSA to rifampin. Rifampin exerted a low MIC (0.02 µg/ml) and was bactericidal in the logarithmic and the stationary growth phases (MBC log and MBC stat 0.09 and 2.4 µg/ml, respectively).
Results
IN VITRO ANTIMICROBIAL SUSCEPTIBILITY
IN VITRO TIME-KILL STUDIES
In the control, the bacterial count increased by 1.7 log 10 cfu/ml after 24 h. Rifampin alone at 1 × MIC decreased the bacterial count after 6 h (-0.5 log 10 cfu/ml); however, regrowth to levels similar to the control was observed after 24 h ( Fig. 1) . A similar result was found for bacteria exposed to rifampin alone at 4 × MIC. When rifampin was combined with hyperthermia at 39°C, 41°C or 43°C, bacterial counts were decreased by 1.3, 1.6 and 1.8 log 10 cfu/ml at 24 h ( Fig. 1) , respectively. Due to the development of rifampin resistance during exposure to rifampin alone, it was not possible to evaluate a potential synergistic or antagonistic interaction between rifampin and hyperthermia.
IN VITRO ANTIMICROBIAL RESISTANCE
Starting from MRSA inocula of 1 -5 × 10 6 cfu/ml, the proportion of rifampin-resistant strains that developed from cultures exposed to rifampin alone at 1 × MIC after 24 h incubation was 94 ± 3%. In contrast, no rifampin-resistant strains were detected after 24 h incubation with the combination of rifampin and hyperthermia at 39°C, 41°C or 43°C.
PHARMACOKINETIC STUDIES
The calculated pharmacokinetic parameters in TCF are summarized in Table 2 . The C max of rifampin in combination with hyperthermia reached about 100 × MIC (1.8, 2.3 and 3.1 µg/ml at 39°C, 41°C and 43°C, respectively) and these were achieved approximately 3 h after dosing. The rifampin concentration remained above the MIC for the test organism at 12 h after dosing (C min 0.3 -0.6 µg/ml) in the rifampin-hyperthermia groups and also in the rifampin alone group (C min 0.1 µg/ml). Table 3 shows bacterial counts of planktonic bacteria and the rates of culture-negative TCF samples immediately before the last antimicrobial dose (day 7) and 3 days after the end of treatment (day 10). Sterility of TCF was confirmed prior to infection. The median concentration of bacteria observed in TCF 24 h after infection was 6.5 log 10 cfu/ml. In control animals receiving saline, bacterial counts in the TCF were 7.1 and 7.9 log 10 cfu/ml at 7 days (immediately before the last antimicrobial dose) and 10 days (3 days after MIC, minimum inhibitory concentration; MBC log , minimum bactericidal concentration in the logarithmic growth phase; MBC stat , minimum bactericidal concentration in the stationary growth phase. Rifampin and focal hyperthermia for foreign-body infections the end of treatment), respectively, corresponding to an increase of 0.6 and 1.4 log 10 cfu/ml on days 7 and 10, respectively (Fig. 2) . No spontaneous cure of cageassociated infection occurred in untreated animals. Bacterial counts at day 7 in the TCF of rabbits treated with rifampin 12.5 mg/kg alone were decreased by a median of 2.8 log 10 cfu/ml and by 3.0 log 10 cfu/ml at day 10 ( Table 3 , Fig. 2 ) and culture-negativity was achieved in 33% of TCF samples (not statistically significant) ( Table 3) . When combined with hyperthermia at 39°C, 41°C and 43°C, rifampin reduced bacterial counts by 2.9, > 3.0 and > 3.0 log 10 cfu/ml at day 7, and by > 3.0 log 10 cfu/ml for all three temperatures at day 10 (P < 0.05 compared with rifampin alone). The cure rate of rabbits treated with the rifampin-hyperthermia combination ranged from 50% to 75% on day 7 and from 70% to 95% on day 10, without emergence of rifampin-resistance.
ANTIMICROBIAL EFFICACY AGAINST PLANKTONIC BACTERIA
ANTIMICROBIAL EFFICACY AGAINST ADHERENT BACTERIA
No cure of cage-associated infections was observed with saline alone (Fig. 3) . Hyperthermia in combination with rifampin showed cure rates of 50 -80%. All hyperthermia and rifampin combinations exhibited significantly better activities than saline and rifampin alone against adherent bacteria (P < 0.01).
IN VIVO ANTIMICROBIAL RESISTANCE STUDIES
Rifampin resistance was not observed, either in TCF or in cover-slips, when used in combination with hyperthermia, whereas it was detected in 100% of cases in the group treated with rifampin alone.
Discussion
In this study, the impact of hyperthermia alone, or in combination with rifampin, against MRSA, was investigated in vitro and in a rabbit implant-associated infection model. The results provide information that may be useful when treating patients with staphylococcal orthopaedic prosthetic or other biomaterial-associated infections. Hyperthermia is part of a host's response to infection and has been demonstrated to be associated with improved outcomes, 25 -28 due, at least in part, to apparent restriction of bacterial growth. Experimental studies with S. pneumoniae meningitis, using rabbits whose body temperature was artificially elevated either before 29 or after 30 infection, demonstrated reduced in vivo bacterial growth rates. The strain of S. pneumoniae used in these studies was unable to grow at 41°C in either pooled cerebrospinal fluid or TSB. 30 The present study extends these observations to experimental foreign-body infection by S. aureus and demonstrates that the test organism was inhibited by focal hyperthermia at ≥ 39°C. A reduction of > 99.9% cfu/ml was not, however, achieved at temperatures up to 43°C, either in logarithmic or in stationary growth phase. Based on this characteristic, hyperthermia alone does not seem to be appropriate for the treatment of staphylococcal implantassociated infections. In the in vitro time-kill curve studies, rifampin-resistance was detected after 24 h of incubation in cultures exposed to rifampin alone (1 × and 4 × the MIC). Macroscopic bacterial growth at the end of 24-h kill curves using hyperthermia plus rifampin was not observed.
In the pharmacokinetic studies, the C max for rifampin in TCF increased linearly with increasing temperature and the AUC 0 -24 increased in proportion to the temperature, reaching their maximum values in TCF exposed to 43°C. The most important mechanisms for an interactive effect are an increased intracellular drug uptake, enhanced DNA damage and higher drug concentrations, resulting from an increase in blood flow. 24 Many drugs are potentiated by heat and it has been shown that hyperthermia can counteract drug resistance of mitomycin C, nitrosoureas, cisplatin, doxorubicin and mitoxantrone in cancer Values are means ± SD from three animals, as predicted by the WinNonlin software package. chemotherapy. 23 This can be explained by a change in perfusion distribution, as found during whole body hyperthermia. 38, 39 The MRSA infection of cages implanted into rabbits demonstrated continuous bacterial growth in the TCF over 10 days and no spontaneous cure. During treatment, bacterial killing in response to rifampin was significantly improved when the drug was administered in combination with hyperthermia compared with rifampin alone (P < 0.05). Three days after the end of treatment (day 10), bacterial re-growth occurred in rabbits treated with rifampin alone.
Combinations of all three hyperthermic conditions plus rifampin inhibited bacterial re-growth on day 3 after the end of treatment (day 10). Treatment failures were related to a lack of efficacy in the killing of bacteria when embedded into the biofilm matrix.
The rabbit tissue cage model of foreignbody infection has been widely established to evaluate the effects of antibiotic therapies, and it has been shown that these antibiotics remained curative when maintained for a long time. 30 The antimicrobial efficacy of hyperthermia given in combination with Counts of planktonic bacteria in tissue cage fluid (TCF) and the rate of culture-negative TCF samples immediately before the last antimicrobial dose (day 7) and 3 days after the end of treatment (day 10)
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rifampin and the protection offered by this combination against the emergence of rifampin-resistant strains were evaluated in the present study. In comparison with rifampin alone, the protective effect of rifampin in combination with hyperthermia against the development of rifampin resistance was clearly observed on day 10 (3 days after the end of treatment). In contrast, in the in vivo studies, resistance to rifampin was detected in 100% of cases treated with rifampin alone, meaning that rifampin alone was ineffective. The evaluation of efficacy over time, i.e. at the end of 7 and 10 days, showed significant and progressive improvement with the rifampin-hyperthermia combination.
In conclusion, rifampin alone showed only moderate efficacy in the rabbit model of foreign-body infection by S. aureus used in the present study, whereas it prevented the emergence of rifampin resistance when used in combination with hyperthermia. The efficacy of this combination therapy was similar to that of rifampin alone during the first days of therapy but increased over time, thereby suggesting an ability to protect against the development of resistance and maintain the benefits of rifampin activity against staphylococcal foreign-body infections.
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